Literature DB >> 20381875

Handwriting movement kinematics for quantifying extrapyramidal side effects in patients treated with atypical antipsychotics.

Michael P Caligiuri1, Hans-Leo Teulings, Charles E Dean, Alexander B Niculescu, James B Lohr.   

Abstract

Ongoing monitoring of neuroleptic-induced extrapyramidal side effects (EPS) is important to maximize treatment outcome, improve medication adherence and reduce re-hospitalization. Traditional approaches for assessing EPS such as Parkinsonism, tardive akathisia, or dyskinesia rely upon clinical ratings. However, these observer-based EPS severity ratings can be unreliable and are subject to examiner bias. In contrast, quantitative instrumental methods are less subject to bias. Most instrumental methods have only limited clinical utility because of their complexity and costs. This paper describes an easy-to-use instrumental approach based on handwriting movements for quantifying EPS. Here, we present findings from psychiatric patients treated with atypical (second generation) antipsychotics. The handwriting task consisted of a sentence written several times within a 2 cm vertical boundary at a comfortable speed using an inkless pen and digitizing tablet. Kinematic variables including movement duration, peak vertical velocity and the number of acceleration peaks, and average normalized jerk (a measure of smoothness) for each up or down stroke and their submovements were analyzed. Results from 59 psychosis patients and 46 healthy comparison subjects revealed significant slowing and dysfluency in patients compared to controls. We observed differences across medications and daily dose. These findings support the ecological validity of handwriting movement analysis as an objective behavioral biomarker for quantifying the effects of antipsychotic medication and dose on the motor system. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20381875      PMCID: PMC2859992          DOI: 10.1016/j.psychres.2009.07.005

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  32 in total

Review 1.  Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome.

Authors:  Rajiv Tandon; Michael D Jibson
Journal:  Ann Clin Psychiatry       Date:  2002-06       Impact factor: 1.567

2.  Treatment predictors of extrapyramidal side effects in patients with tardive dyskinesia: results from Veterans Affairs Cooperative Study 394.

Authors:  James B Lohr; Michael P Caligiuri; Robert Edson; Philip Lavori; Lenard A Adler; John Rotrosen; Robert Hitzemann
Journal:  J Clin Psychopharmacol       Date:  2002-04       Impact factor: 3.153

3.  A rating scale for extrapyramidal side effects.

Authors:  G M Simpson; J W Angus
Journal:  Acta Psychiatr Scand Suppl       Date:  1970

Review 4.  Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient.

Authors:  S Kapur; G Remington
Journal:  Biol Psychiatry       Date:  2001-12-01       Impact factor: 13.382

5.  The purely neuroleptic effects and its relation to the "neuroleptic threshold".

Authors:  H J Haase
Journal:  Acta Psychiatr Belg       Date:  1978 Jan-Feb

6.  [Diminution of hand writing area and D2-dopamine receptor blockade. Results from treatment with typical and atypical neuroleptics].

Authors:  U Künstler; K Hohdorf; R Regenthal; A Seese; H J Gertz
Journal:  Nervenarzt       Date:  2000-05       Impact factor: 1.214

Review 7.  Effects of newer antipsychotics on extrapyramidal function.

Authors:  Daniel Tarsy; Ross J Baldessarini; Frank I Tarazi
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

8.  Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.

Authors:  Stephen R Marder; Robert D McQuade; Elyse Stock; Stephen Kaplita; Ronald Marcus; Allan Z Safferman; Anutosh Saha; Mirza Ali; Taro Iwamoto
Journal:  Schizophr Res       Date:  2003-06-01       Impact factor: 4.939

9.  Handwriting movement analyses for monitoring drug-induced motor side effects in schizophrenia patients treated with risperidone.

Authors:  Michael P Caligiuri; Hans-Leo Teulings; Charles E Dean; Alexander B Niculescu; James Lohr
Journal:  Hum Mov Sci       Date:  2009-08-18       Impact factor: 2.161

10.  The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.

Authors:  John M Kane; Stefan Leucht; Daniel Carpenter; John P Docherty
Journal:  J Clin Psychiatry       Date:  2003       Impact factor: 4.384

View more
  24 in total

1.  The nature of bradykinesia in schizophrenia treated with antipsychotics.

Authors:  Michael P Caligiuri; Hans-Leo Teulings; Charles E Dean; James B Lohr
Journal:  Psychiatry Res       Date:  2019-01-15       Impact factor: 3.222

2.  As Motor System Pathophysiology Returns to the Forefront of Psychosis Research, Clinical Implications Should Hold Center Stage.

Authors:  Vijay A Mittal; Sebastian Walther
Journal:  Schizophr Bull       Date:  2019-04-25       Impact factor: 9.306

3.  Extrapyramidal examinations in psychiatry.

Authors:  Richard D Sanders; Paulette Marie Gillig
Journal:  Innov Clin Neurosci       Date:  2012-07

4.  Longitudinal Assessment and Functional Neuroimaging of Movement Variability Reveal Novel Insights Into Motor Dysfunction in Clinical High Risk for Psychosis.

Authors:  Derek J Dean; Jessica A Bernard; Katherine S F Damme; Randall O'Reilly; Joseph M Orr; Vijay A Mittal
Journal:  Schizophr Bull       Date:  2020-12-01       Impact factor: 9.306

5.  Instrument-based assessment of motor function yields no evidence of dyskinesia in adult first-degree biological relatives of individuals with schizophrenia and schizoaffective disorder.

Authors:  Jerillyn S Kent; Michael P Caligiuri; Mallory K Skorheim; Timothy J Lano; Vijay A Mittal; Scott R Sponheim
Journal:  Psychiatry Res       Date:  2018-12-06       Impact factor: 3.222

6.  Motor clusters reveal differences in risk for psychosis, cognitive functioning, and thalamocortical connectivity: evidence for vulnerability subtypes.

Authors:  Derek J Dean; Sebastian Walther; Jessica A Bernard; Vijay A Mittal
Journal:  Clin Psychol Sci       Date:  2018-05-31

7.  Motion energy analysis reveals altered body movement in youth at risk for psychosis.

Authors:  Derek J Dean; Alayna T Samson; Raeana Newberry; Vijay A Mittal
Journal:  Schizophr Res       Date:  2017-06-03       Impact factor: 4.939

8.  Sensorimotor and Activity Psychosis-Risk (SMAP-R) Scale: An Exploration of Scale Structure With Replication and Validation.

Authors:  Katherine S F Damme; Jason Schiffman; Lauren M Ellman; Vijay A Mittal
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

9.  Motor behavior reflects reduced hemispheric asymmetry in the psychosis risk period.

Authors:  Derek J Dean; Joseph M Orr; Raeana E Newberry; Vijay A Mittal
Journal:  Schizophr Res       Date:  2015-10-20       Impact factor: 4.939

10.  [Antipsychotic-induced motor symptoms in schizophrenic psychoses-Part 3 : Tardive dyskinesia].

Authors:  D Hirjak; K M Kubera; S Bienentreu; P A Thomann; R C Wolf
Journal:  Nervenarzt       Date:  2019-05       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.